By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is ...

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

Shares in Valneva slumped around 25% on Monday after the French drugmaker said the United States Food and Drug Administration ...

US health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...

Mainland France has seen an explosion of chikungunya outbreaks this summer and local officials are hunting down the tiger mosquitoes responsible for spreading the virus. Meanwhile, the United States ...

Reports of side effects have prompted reviews in particular over its use in older patients. Read more at straitstimes.com.

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

US health authorities have suspended the licence of the Ixchiq vaccine, used against the mosquito-borne chikungunya virus, after reports of serious side effects in several patients, including elderly ...

The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of Ixchiq in the United States. The suspension follows the US FDA’s decision on August 6, 20251 ...